Abstract Details

Title Investigation of S-Nitrosoglutathione in Stroke: A Systematic Review and Meta-Analysis of Literature in Pre-clinical and Clinical Research

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P1 - Poster Session 1 (12:00 PM-1:00 PM)

Poster/Presentation
Number 4-001

Objective To conduct a systematic review on the published literatures using S-Nitrosoglutathione (GSNO) in both pre-clinical and clinical stroke studies.

Background GSNO is a nitric oxide donor that has been investigated for neuroprotective and neuro-recovery effect.

Design/Methods We searched PubMed up to August 1st, 2018, using the following keywords: S-Nitrosoglutathione, GSNO, stroke, cerebrovascular, carotid arteries, middle cerebral artery, and middle cerebral artery occlusion. Only studies published in the English language providing efficacy results of GSNO on ischemic stroke were included. Stroke Therapy Academic Industry Roundtable (STAIR) score was used to assess the quality of pre-clinical studies and PEDro score for clinical trials. A meta-analysis was conducted to compare the effect size.

Results

Of 39 articles identified, 10 (6 for pre-clinical and 4 for clinical studies) met the eligibility criteria and were included. The median STAIR score across the pre-clinical studies was 5.5 (range: 4-7), and the median PEDro score for the 4 clinical trials was 10 (ranged: 6 to 10). Among the 6 pre-clinical studies, GSNO reduced infarct size in 6 studies and improved neurological behavior scales in 5 studies compared to placebo. Inverse-variance weighted linear meta-analysis of standardized mean difference (Hedge’s g) on 4 human studies revealed a big effect size (Hedge’s g = -0.82, 95% CI: [-1.26, -0.38], P=0.0003) favoring the GSNO group in term of reducing embolic signals. I² value was 0 across the included clinical studies in the meta-analysis.

Conclusions Pre-clinical and clinical studies showed potential benefit of GSNO for acute ischemic stroke. Further investigation of this molecule is warranted.

Authors/Disclosures
Shimeng Liu, MD, PhD (Beijing Tiantan Hospital, Capital Medical University) PRESENTER	No disclosure on file
	No disclosure on file
Wengui Yu, MD, PhD (UC Irvine, Neurology Dept)	Dr. Yu has nothing to disclose.
	No disclosure on file
Shreyansh Shah, MD (Massachusetts General Hospital, Brigham, Harvard)	No disclosure on file
	No disclosure on file
Inderjit Singh, PhD (Medical University of South Carolina)	No disclosure on file
Carmelo Graffagnino, MD (Duke University Medical Center)	No disclosure on file
Wayne W. Feng, MD, FAAN (Duke University School of Medicine)	Dr. Feng has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Namsa. The institution of Dr. Feng has received research support from NIH. The institution of Dr. Feng has received research support from American heart association . The institution of Dr. Feng has received research support from Ipsen.